Chemotherapy for Diffuse Aggressive Lymphomas
Authors: RICHARD S. STEIN
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 September 1984Chemotherapy for Diffuse Aggressive LymphomasRICHARD S. STEIN, M.D.RICHARD S. STEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-3-397 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Although Fisher and associates (1) have proclaimed ProMACE (prednisone, methotrexate, doxorubicin, cyclophosphamide, and epipodophyllotoxin VP-16)-MOPP (mechlorethamine, vincristine sulfate, procarbazine, and prednisone) as a "substantial improvement in the treatment of diffuse aggressive lymphomas as compared with previously used regimens," a careful rereading of their paper suggests that this may not be the case.Their discussion compares the 48% continuous disease-free survival achieved with other regimens, such as COMLA (cyclophosphamide, vincristine, methotrexate, and cytarabine), with the 75% complete remission rate and 65% survival rate achieved with ProMACE/MOPP. However, survival is not disease-free survival. Fisher and associates report a 74%...References1. FISHERDEVITAHUBBARD RVS. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med. 1983;98:304-9. LinkGoogle Scholar2. FISHERHUBBARDDEVITA RSV. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood. 1981;58:45-51. CrossrefMedlineGoogle Scholar3. NEWCOMERNERENBERGCADMAN LME. The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy. Cancer. 1982;50:439-42. CrossrefMedlineGoogle Scholar4. SWEETCOLLINSSTEINULTMANN DRRJ. Prognostic significance of the Lukes and Collins classification in patients treated with COMLA. Cancer Treat Rep. 1982;66:1107-11. MedlineGoogle Scholar1. FISHERDEVITAHUBBARD RVS. Diffuse aggressive lymphomas: increased survival after alternating flexible sequence of ProMACE and MOPP chemotherapy. Ann Intern Med. 1983;98:304-9. LinkGoogle Scholar2. SWEETGOLOMBULTMANN DHJ. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980;92:785-90. LinkGoogle Scholar3. JONESGROZEAMETZ SPE. Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979;43:417-25. CrossrefMedlineGoogle Scholar4. FISHERDEVITAJOHNSONSIMONYOUNG RVBRR. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med. 1977;63:177-82. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1984Volume 101, Issue 3Page: 397-398KeywordsChemotherapyCyclophosphamideDisease free survivalLymphomaMechlorethamineMethotrexateProcarbazineSulfates ePublished: 1 December 2008 Issue Published: 1 September 1984 PDF downloadLoading ...